Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting
25 nov. 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer
21 nov. 2019 16h05 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections
08 nov. 2019 16h05 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results
07 nov. 2019 08h00 HE
|
Progenics Pharmaceuticals Inc.
Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical TherapeuticsAZEDRA...
Progenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent Solicitation
06 nov. 2019 08h00 HE
|
Progenics Pharmaceuticals Inc.
Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus...
Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan’s Nominees Control of the Board
04 nov. 2019 08h00 HE
|
Progenics Pharmaceuticals Inc.
November 17 is the Only Deadline for Velan’s Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 ...
Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent Solicitation
01 nov. 2019 13h00 HE
|
Progenics Pharmaceuticals Inc.
Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents...
Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors
28 oct. 2019 14h00 HE
|
Progenics Pharmaceuticals Inc.
ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of...
Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.
23 oct. 2019 09h55 HE
|
Progenics Pharmaceuticals Inc.
Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks...
Progenics Sends Letter to Shareholders
21 oct. 2019 08h46 HE
|
Progenics Pharmaceuticals Inc.
Calls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics’ WHITE Consent Revocation Card NEW YORK, Oct. 21, 2019 ...